FLAURA study of osimertinib versus TKI for 1st line NSCLC
9 Sep 2017
FLAURA study of osimertinib versus TKI for 1st line NSCLC
Follow-up on the IFCT-0302 trial
PACIFIC trial of durvalumab for lung cancer
ESMO 2017: CDK4/6 inhibitors from a patient’s perspective
Editor's Choice for August 2017
Editor's Choice for July 17
iManageCancer: Serious Games for Kids
Translational research in breast cancer
How to (and how not to) disclose unfavourable diagnostic outcomes: Physician's guide
A step-by-step protocol for disclosing unfavourable diagnostic outcomes
New treatments for lung cancer
The unmet needs of cancer survivors